Skip to main navigation Skip to search Skip to main content

TLK-286

  • Claire F. Verschraegen
  • , Harriet O. Smith
  • , Fa Chyi Lee
  • , Cynthia Cathcart
  • , Jeffery P. Norenberg

Research output: Contribution to journalArticlepeer-review

Abstract

Telik Inc is developing TLK-286, a modified glutathione analog prodrug, for the potential treatment of cancer.

Original languageEnglish (US)
Pages (from-to)771-781
Number of pages11
JournalIDrugs
Volume7
Issue number8
StatePublished - Aug 2004
Externally publishedYes

UN SDGs

This output contributes to the following UN Sustainable Development Goals (SDGs)

  1. SDG 3 - Good Health and Well-being
    SDG 3 Good Health and Well-being

ASJC Scopus subject areas

  • Pharmacology
  • Drug Discovery

Fingerprint

Dive into the research topics of 'TLK-286'. Together they form a unique fingerprint.

Cite this